InsidersTradesSigma
申报总数
公司
▲ 买入（3 笔）
▼ 卖出（0 笔）
内部人交易记录
董事已披露买入
3
已披露卖出
0
T+90 胜率
0%
T+90 平均收益
-32.1%
基于 1 个已确定 T+90 收益的买入信号。收益基准：公布次日的收盘价。
信号历史
Browse the detailed record of transactions filed by Murphy Matthew B., Conseiller Juridique Général. Insider active across 1 company, notably Nautilus Biotechnology, Inc.. Aggregated, 4 filings have been published. Breakdown: 3 buys · 0 sell. Total volume traded: €50k. History available since 13 August 2021. The latest transaction was disclosed on 4 September 2025 (Acquisition). Regulator: SEC (Form 4). The full history is free.
Companies and markets linked to Murphy Matthew B.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报4 总计
20,000 股@ US$0.642913.5% 占其流量Common StockSEC:0001865778-25-000003:0
标准退出：2025年12月3日 (T+90)
2,500 股@ US$2.856.7% 占其流量Common StockSEC:0001808805-22-000093:0
标准退出：2022年11月10日 (T+90)
10,000 股@ US$3.2838.7% 占其流量Common StockSEC:0001808805-22-000056:0
5,000 股@ US$7.561339.4% 占其流量Common StockSEC:0001808805-21-000010:0
标准退出：2021年11月11日 (T+90)
4 条申报中的 4 条
About Murphy Matthew B.
Matthew B. Murphy is the General Counsel at Nautilus Biotechnology, Inc. In this role, he is responsible for the company's legal affairs and compliance. His expertise in business law is essential for advising management on legal and regulatory matters. He plays a key role in managing legal risks and protecting the company's interests.
